Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Condition(s) studied

Investigational drug(s) / intervention(s)

Catheter ablation: Ablation using Biosense Webster, Inc. (BWI) CARTO™ technologies (e.g., THERMOCOOL SMARTTOUCH® SF, QDOT MICRO™, VARIPULSE™). Future new Biosense Webster, Inc. technologies, including new thermal and/or pulsed field ablation (PFA), may be included as they become commercially available.

Study summary

The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.

Eligibility

Primary outcome measure(s)

• Effectiveness at 90 days — 90 days
  Freedom from arrhythmia recurrence at 90 days post procedure.
• Effectiveness at 12 months — 12 months
  Freedom from subject reported arrhythmia recurrence through 12 months post procedure.
• Long-term Safety — 30 days post ablation
  Incidence of late onset complications, 30 days post-ablation which are procedure and/or device related

Trial sites (75)

+ 35 more sites — see the full list on the official registry below.

Other trials for the same condition